CHILDREN'S TYLENOL PLUS FLU OTC
Generic Name and Formulations:
Acetaminophen 160mg, chlorpheniramine maleate 1mg, dextromethorphan HBr 5mg, phenylephrine HCl 2.5mg; per 5mL; liq; bubble-gum flavor.
McNeil Consumer Healthcare
Indications for CHILDREN'S TYLENOL PLUS FLU:
Nasal congestion, rhinorrhea, sore throat, cough, headache, fever, minor aches and pains.
<4yrs (<36lbs): do not use. 4–5yrs (36lbs–47lbs): not recommended. 6–11yrs (48–95lbs): 10mL every 4 hours as needed; max 5 doses/24 hours.
Children <4yrs (<36lbs). During or within 14 days of MAOIs. Concomitant other acetaminophen products. For use as a sedative hypnotic.
Hepatic dysfunction. Cardiovascular disease. Hypertension. Thyroid disease. Glaucoma. GI or GU obstruction. Diabetes. Asthma. Lower respiratory disorders.
Analgesic + antihistamine + antitussive + sympathomimetic.
See Contraindications. Hypertensive crisis with MAOIs. β-blockers may increase pressor effects of sympathomimetics. Antihypertensives antagonized. Increased CNS effects with other CNS depressants.
Drowsiness, anticholinergic effects, nervousness, dizziness, insomnia, excitability, hepatotoxicity (overdosage).
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline